Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 88

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 88
---
2642 |     | August 29, 2018   |     |         3142642 |     | April 8, 2035 |
| Granted |     | EP-CH   |     | Oct. 11, 2016 |     | Liposomal Mupirocin |     |      3142642 |     | August 29, 2018   |     |         3142642 |     | April 8, 2035 |
| Granted |     | EP-GB   |     | Oct. 11, 2016 |     | Liposomal Mupirocin |     |      3142642 |     | August 29, 2018   |     |         3142642 |     | April 8, 2035 |
| Granted |     | CN      |     | Oct. 10, 2016 |     | Liposomal Mupirocin |     |    106659795 |     | June 2, 2023      |     |       106659795 |     | April 8, 2035 |
| Granted |     | JP      |     | Oct. 6, 2016  |     | Liposomal Mupirocin |     |  2017-513938 |     | March 13, 2020    |     |         6676035 |     | April 8, 2035 |
| Granted |     | IN      |     | Oct. 19, 2016 |     | Liposomal Mupirocin |     | 201627035738 |     | November 23, 2020 |     |          351893 |     | April 8, 2035 |

Pursuant to the Yissum License Agreements,
we have an exclusive, worldwide license for the development, use, manufacture and commercialization of products arising out of patents
owned by, and patent applications filed by, Yissum in connection with Liposomal formulation of Nano-Mupirocin . All of patents and patent
applications listed below were licensed to us by Yissum pursuant to the Yissum License Agreements.

Market Opportunity and Estimated Commercial Potential for Systemic Liposomal Nano-Mupirocin

Clinical Background and Unmet Need

Gonorrhea, caused by Neisseria gonorrhoeae,
is one of the most common sexually transmitted infections globally. The U.S. Centers for Disease Control and Prevention (CDC